Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh-mismatched transfusions...

Area of Science:

• Transfusion Medicine
• Immunology
• Pediatric Hematology

Background:

• RhD-negative women transfused with RhD-positive blood risk alloimmunization, impacting future pregnancies and causing hemolytic disease of the fetus and newborn (HDFN).
• Increased use of RhD-positive blood products in pediatric trauma highlights an unaddressed alloimmunization risk for RhD-negative girls.
• Existing literature lacks specific guidelines for managing RhD-negative pediatric females receiving RhD-positive transfusions.

Purpose of the Study:

• To establish a best-practice guideline for managing RhD-negative pediatric females who receive RhD-positive transfusions.
• To mitigate the risk of RhD alloimmunization in this vulnerable pediatric population.
• To safeguard future reproductive outcomes for RhD-negative girls who receive mismatched transfusions.

Main Methods:

• Notification of RhD-mismatched transfusions to pathology or transfusion medicine staff.
• Eligibility for Rh immunoglobulin (RhIG) therapy determined based on transfused red blood cell volume (RBCv) relative to total blood volume (TBV).
• Evaluation and counseling by Pediatrics or Pediatric Hematology, with treatment offered as appropriate.

Main Results:

• Management strategy is contingent on the volume of red blood cells transfused (RBCv).
• Pediatric females receiving <20% of their TBV as RBCv are eligible for RhIG; those receiving >20% are not.
• All patients require screening for anti-D antibodies 6-12 months post-transfusion and follow-up by ObGyn before pregnancy.

Conclusions:

• Published guidelines for managing mismatched transfusions in pediatric patients are lacking.
• The proposed approach offers a framework to safely manage RhD-negative pediatric females receiving RhD-positive transfusions.
• This management strategy aims to prevent RhD alloimmunization and protect reproductive health.